The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group
Abstract
To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received antithyroid drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with antithyroid drugs are important factors to consider when selecting therapy for Graves' disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY
TUNBRIDGE, W. M. G., EVERED, D. C., HALL, R., APPLETON, D., BREWIS, M., CLARK, F., EVANS, J. G., YOUNG, E., BIRD, T., & SMITH, P. A. (1977) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1977.tb01340.x · Cited by 2,674
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Self-citationCurrent Trends in the Management of Graves' Disease*
SOLOMON, B., GLINOER, D., LAGASSE, R., & WARTOFSKY, L. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-6-1518 · Cited by 266
ALLANNIC, H., FAUCHET, R., ORGIAZZI, J., ORGIAZZI, A. M., GENETET, B., LORCY, Y., GUERRIER, A. M. L., DELAMBRE, C., & DERENNES, V. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-675 · Cited by 193
Long-Term Follow-up Study of Compensated Low-Dose131I Therapy for Graves' Disease
Sridama, V., McCormick, M., Kaplan, E. L., Fauchet, R., & DeGroot, L. J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408163110702 · Cited by 190
Reinwein, D. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.6.1516 · Cited by 180
Tallstedt, L., Lundell, G., Blomgren, H., & Bring, J. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300494 · Cited by 171
Self-citationTreatment of Hyperthyroidism With Sodium Iodide I 131: A 16-Year Experience
Nofal, M. M. (1966) · JAMA · doi:10.1001/jama.1966.03110080045015 · Cited by 165
ROMALDINI, J. H., BROMBERG, N., WERNER, R. S., TANAKA, L. M., RODRIGUES, H. F., WERNER, M. C., TANAKA, L. M., RODRIGUES, H. F., WERNER, M. C., FARAH, C. S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-563 · Cited by 164
PREDICTION OF RELAPSE IN HYPERTHYROID GRAVES' DISEASE
McGregor, A. M., Smith, B. R., Hall, R., Petersen, M. M., Miller, M. A., & Dewar, P. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91551-2 · Cited by 153
Davies, T. F., Evered, D. C., Smith, B. R., Yeo, P. P., CLARK, F., & Hall, R. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92719-2 · Cited by 135
Tötterman, T. H., Karlsson, F. A., Bengtsson, M., & Mendel-Hartvig, I. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701013160104 · Cited by 131
TENG, C. S., & YEUNG, R. T. T. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-144 · Cited by 130
Glinoer, D., Hesch, D., Lagasse, R., & Laurberg, P. (1987) · European Journal of Endocrinology · doi:10.1530/acta.0.115s006 · Cited by 117
Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism.
Holm, L., Lundell, G. E. F., Israelsson, A., & Dahlqvist, I. (1982) · PubMed · Cited by 100
Thionamide Therapy in Graves' Disease: Relation of Relapse Rate to Duration of Therapy
Tamai, H., NAKAGAWA, T., FUKINO, O., OHSAKO, N., SHINZATO, R., SUEMATSU, H., KUMA, K., MATSUZUKA, F., & NAGATAKI, S. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-4-488 · Cited by 89
Petersen, K. L., Lindstedt, G., Lundberg, P. A., Bengtsson, C., Lapidus, L., & Nyström, E. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00367.x · Cited by 78
SUGRUE, D. D., McEvoy, M., Feely, J., & Drury, M. I. (1980) · QJM · doi:10.1093/oxfordjournals.qjmed.a067604 · Cited by 67
THYROID STIMULATING ANTIBODIES: AN AID TO THE STRATEGY OF TREATMENT OF GRAVES' DISEASE?
Madec, A., Laurent, M. C., LORCY, Y., GUERRIER, A. M. L., Rostagnat-Stefanutti, A., Orgiazzi, J., & Allannic, H. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb03466.x · Cited by 62
Berglund, J., Christensen, S. B., Dymling, J. ‐., & Hallengren, B. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00371.x · Cited by 57
And, K. B., & Madsen, S. N. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03406.x · Cited by 57
Andåker, L., Johansson, K., Smeds, S., & Lennquist, S. (1992) · World Journal of Surgery · doi:10.1007/bf02067381 · Cited by 54
The Management of Hyperthyroidism Due to Graves' Disease in Japan in 1988.
Nagayama, Y., Izumi, M., & Nagataki, S. (1989) · Endocrinologia Japonica · doi:10.1507/endocrj1954.36.299 · Cited by 47
Factors influencing the outcome of thyrostatic drug therapy in Graves' disease
Winsa, B., Dahlberg, P. A., Jansson, R., Ågren, H., & Karlsson, F. A. (1990) · European Journal of Endocrinology · doi:10.1530/acta.0.1220722 · Cited by 46
Importance of tsh receptor activation in the development of severe endocrine ophthalmopathy
Karlsson, F. A., Dahlberg, P. A., Jansson‐Löfmark, R., et al. (1989) · European Journal of Endocrinology · Cited by 40
Lg, L. (1955) · PubMed · Cited by 31
Gamstedt, A., WADMAN, B., & KARLSSON, A. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-4-773 · Cited by 30
The surgical treatment of Graves' disease.
Ménégaux, F., Ruprecht, T., & Jp, C. (1993) · PubMed · Cited by 29
Differences and Similarities in the Treatment of Diffuse Goiter in Europe and the United States
Wartofsky, L., Glinoer, D., Solomon, B. J., & Lagasse, R. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211072 · Cited by 27
Management of Graves’ Hyperthyroidism
Orgiazzi, J. (1987) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30484-5 · Cited by 26
The management of Graves' disease in New Zealand: results of a national survey.
Hc, F., Jw, D., & Cm, F. (1991) · PubMed · Cited by 13
Cited by
Cooper, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042972 · Cited by 1,008
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Brent, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801880 · Cited by 594
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0020 · Cited by 489
Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428
Self-citation
Metadata
- Authors
- Torring, O.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1996-08-01
- Volume
- 81
- Issue
- 8
- Pages
- 2986-2993
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2002476906
- Cited by
- 311
- References
- 31
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.